Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport
- 1 March 2014
- journal article
- review article
- Published by Elsevier BV in Kidney International
- Vol. 85 (3), 522-528
- https://doi.org/10.1038/ki.2013.399
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- In vitro microvessels for the study of angiogenesis and thrombosisProceedings of the National Academy of Sciences of the United States of America, 2012
- The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearanceXenobiotica, 2011
- Hepatic Clearance, but Not Gut Availability, of Erythromycin Is Altered in Patients With End-Stage Renal DiseaseClinical Pharmacology & Therapeutics, 2010
- ESRD Impairs Nonrenal Clearance of Fexofenadine but not MidazolamJournal of the American Society of Nephrology, 2009
- Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytesAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2008
- The effect of chronic renal failure on drug metabolism and transportExpert Opinion on Drug Metabolism & Toxicology, 2008
- Prevalence of Chronic Kidney Disease in the United StatesJAMA, 2007
- Review on uremic toxins: Classification, concentration, and interindividual variabilityKidney International, 2003
- Down‐regulation of hepatic cytochrome P450 in chronic renal failure: role of uremic mediatorsBritish Journal of Pharmacology, 2002
- Pharmacokinetics and Effects of Propranolol in Terminal Uraemic Patients and in Patients Undergoing Regular Dialysis Treatment1Clinical Pharmacokinetics, 1976